Dec 10, 2022 Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial
Dec 5, 2022 Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10
Nov 14, 2022 Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
Nov 3, 2022 Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting
Sep 16, 2022 Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
